孟德尔随机化
疾病
炎症
药品
肿瘤坏死因子α
医学
免疫学
生物
药理学
生物信息学
遗传学
内科学
基因
遗传变异
基因型
标识
DOI:10.1016/j.intimp.2024.112786
摘要
There are only a few recognized drug targets for cerebral small vessel disease (CSVD). Though inflammation is increasingly implicated in the development of CSVD, it remains unclear whether immunomodulation could become a therapeutic target. Accordingly, the Mendelian randomization (MR) method was used to assess the genetically proxied impacts of IL6 receptor (IL6R) inhibitor, IL1β inhibitor, Tumor necrosis factor (TNF) inhibitor and β-tubulin inhibitor on CSVD through.
科研通智能强力驱动
Strongly Powered by AbleSci AI